Diamedica Therapeutics Inc (DMAC) - News Archive

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, is making noteworthy strides in its mission to develop innovative therapies for conditions such as preeclampsia, fetal growth restr...

Strategic Advancements and Scientific Progress at DiaMedica Therapeutics: A Look at Recent Developments MINNEAPOLIS DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company at the forefront...

DiaMedica Therapeutics Closes $30.1 Million Private Placement Amidst Financial Challenges DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company headquartered in Minneapolis, recently ann...

In a significant advancement for women s health, DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company based in Minneapolis, has reported compelling interim results from Part 1a of its P...

In an era marked by remarkable advancements in healthcare, one company is positioning itself at the forefront of biopharmaceutical innovation. DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutic...

CSIMarket.com In an ever-evolving landscape of biopharmaceutical innovation, DiaMedica Therapeutics Inc. (NASDAQ: DMAC) stands at a crucial juncture as it prepares to participate in key investor conferences in May 2025,...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, is strategically positioning itself within the healthcare sector through innovative approaches in treating severe ischemic diseases...

Innovative Pursuits in Preeclampsia Treatment: DiaMedica Therapeutics Embarks on Phase 2 Trial of DM199 In the pursuit of advanced therapeutic interventions for preeclampsia (PE), a formidable condition prevalent in obs...

In an exciting development for maternal health, DiaMedica Therapeutics Inc. (Nasdaq: DMAC), the Minneapolis-based biopharmaceutical company renowned for its commitment to advancing treatments for severe ischemic disease...

DiaMedica Therapeutics Inc. a biopharmaceutical company based in Minneapolis and listed on the Nasdaq under the ticker DMAC, is poised to release its financial results for the third quarter of 2024. The financial report...

Preeclampsia, a complex hypertensive disorder occurring during pregnancy, poses significant risks to maternal and fetal health. New therapeutic strategies to address this condition are urgently needed. DiaMedica Therape...

DiaMedica Therapeutics to Participate in September Conferences Amidst Financial Challenges DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, has recently announced its participation...

Breakthrough in Ischemic Disease Therapeutics: A Business and Financial Update from DiaMedica Therapeutics In the ever-evolving landscape of pharmaceutical sciences, the innovative strides taken by clinical-stage biopha...

: This article presents a summary of recent developments at DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on novel treatments for severe ischemic diseases. This analysis...

Minneapolis, MN In a significant move for its stakeholders, DiaMedica Therapeutics Inc. (Nasdaq: DMAC) has announced the release of its second quarter 2024 financial results, scheduled for August 7, 2024, after markets...

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company specializing in the development of novel therapies for severe ischemic disease, recently released a comprehensive white paper on preeclampsia and a...

Diamedica Therapeutics Inc (NASDAQ: DMAC) has recently witnessed a decline in the performance of its shares, lagging behind the overall market. This article aims to explore the reasons behind this under-performance by i...

DiaMedica Therapeutics Announces $11.8 Million Private Placement with Accredited Investors Minneapolis DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company dedicated to developing novel...

MINNEAPOLIS - DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a leading clinical-stage biopharmaceutical company, has provided a comprehensive business update and encouraging financial results for the first quarter ended Ma...